TALIPEXOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H15N3S
Molecular Weight	209.311
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DHSSDEDRBUKTQY-UHFFFAOYSA-N

InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)

HIDE SMILES / InChI

Molecular Formula	C10H15N3S
Molecular Weight	209.311
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	5.8 null [pKi]
Dopamine D3 receptor 91 Target ID: CHEMBL234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	7.0 null [pKi]
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.43 null [pKi]
Alpha-2b adrenergic receptor 27 Target ID: CHEMBL1942 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.09 null [pKi]
Alpha-2c adrenergic receptor 37 Target ID: CHEMBL1916 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.37 null [pKi]
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	6.48 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic schizophrenia 6 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8102551	Primary		Preclinical	Unknown Approved Use Unknown
Parkinson's disease 226 Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.	2001 May	11383713
Intranasal application of the alpha2-adrenoceptor agonist BHT-920 produces decongestion in the cat.	2001 Nov-Dec	11777250
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.	2003 Apr	12649387
An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder.	2004 May 1	15164915
Drug treatment of Parkinson's disease.	2004 Sep	22033779
Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice.	2006	16569938
Pre-junctional alpha2-adrenoceptors modulation of the nitrergic transmission in the pig urinary bladder neck.	2007	17266136
MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine.	2007 Sep	18404453
Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.	2008 Apr 30	18074382
The frequency of cardiac valvular regurgitation in Parkinson's disease.	2008 May 15	18398916
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.	2009 Feb	19146631
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.	2010 May	21209752

Patents

Sample Use Guides

In Vivo Use Guide

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day

Route of Administration: Oral

In Vitro Use Guide

Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:37:10 GMT 2023` Edited by `admin` on `Fri Dec 15 17:37:10 GMT 2023`
Record UNII	7AM2J46Z1Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALIPEXOLE

Official Name

English

6-ALLYL-2-AMINO-5,6,7,8-TETRAHYDRO-4H-THIAZOLO(4,5-D)AZEPINE

Systematic Name

English

talipexole [INN]

Common Name

English

Talipexole [WHO-DD]

Common Name

English

TALIPEXOLE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66884